Literature DB >> 11463607

Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling.

Y Hoshikawa1, N F Voelkel, T L Gesell, M D Moore, K G Morris, L A Alger, S Narumiya, M W Geraci.   

Abstract

Prostacyclin (PGI(2)) reduces pulmonary vascular resistance and attenuates vascular smooth muscle cell proliferation through signal transduction following ligand binding to its receptor. Because patients with severe pulmonary hypertension have a reduced PGI(2) receptor (PGI-R) expression in the remodeled pulmonary arterial smooth muscle, we hypothesized that pulmonary vascular remodeling may be modified PGI-R dependently. To test this hypothesis, PGI-R knockout (KO) and wild-type (WT) mice were subjected to a simulated altitude of 17,000 ft or Denver altitude for 3 wk, and right ventricular pressure and lung histology were assessed. The PGI-R KO mice developed more severe pulmonary hypertension and vascular remodeling after chronic hypoxic exposure when compared to the WT mice. Our results indicate that PGI(2) and its receptor play an important role in the regulation of hypoxia-induced pulmonary vascular remodeling, and that the absence of a functional receptor worsens pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11463607     DOI: 10.1164/ajrccm.164.2.2010150

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  39 in total

Review 1.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

Review 2.  [Consensus recommendations of the Pulmonary Arterial Hypertension Study Group of the Austrian Society of Lung Diseases and Tuberculosis].

Authors:  Rolf Ziesche
Journal:  Wien Klin Wochenschr       Date:  2003-05-30       Impact factor: 1.704

3.  Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension.

Authors:  Helen Christou; Ossama M Reslan; Virak Mam; Alain F Tanbe; Sally H Vitali; Marlin Touma; Elena Arons; S Alex Mitsialis; Stella Kourembanas; Raouf A Khalil
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-27       Impact factor: 5.464

4.  EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling.

Authors:  Ankang Lu; Caojian Zuo; Yuhu He; Guilin Chen; Lingjuan Piao; Jian Zhang; Bing Xiao; Yujun Shen; Juan Tang; Deping Kong; Sara Alberti; Di Chen; Shenkai Zuo; Qianqian Zhang; Shuai Yan; Xiaochun Fei; Fei Yuan; Bin Zhou; Shengzhong Duan; Yu Yu; Michael Lazarus; Yunchao Su; Richard M Breyer; Colin D Funk; Ying Yu
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

Review 5.  Pulmonary arterial hypertension: the clinical syndrome.

Authors:  Yen-Chun Lai; Karin C Potoka; Hunter C Champion; Ana L Mora; Mark T Gladwin
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

6.  Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling.

Authors:  Brian B Graham; Margaret M Mentink-Kane; Hazim El-Haddad; Shawn Purnell; Li Zhang; Ari Zaiman; Elizabeth F Redente; David W H Riches; Paul M Hassoun; Angela Bandeira; Hunter C Champion; Ghazwan Butrous; Thomas A Wynn; Rubin M Tuder
Journal:  Am J Pathol       Date:  2010-07-29       Impact factor: 4.307

7.  Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension.

Authors:  Emilia Falcetti; Susan M Hall; Peter G Phillips; Jigisha Patel; Nicholas W Morrell; Sheila G Haworth; Lucie H Clapp
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

Review 8.  Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment.

Authors:  J L Wright; R D Levy; A Churg
Journal:  Thorax       Date:  2005-07       Impact factor: 9.139

9.  Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in the Sugen-Hypoxia Rat Model.

Authors:  Helen Christou; Hannes Hudalla; Zoe Michael; Evgenia J Filatava; Jun Li; Minglin Zhu; Jose S Possomato-Vieira; Carlos Dias-Junior; Stella Kourembanas; Raouf A Khalil
Journal:  J Pharmacol Exp Ther       Date:  2017-12-06       Impact factor: 4.030

10.  Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury.

Authors:  Rio Dumitrascu; Silke Koebrich; Eva Dony; Norbert Weissmann; Rajkumar Savai; Soni S Pullamsetti; Hossein A Ghofrani; Arun Samidurai; Horst Traupe; Werner Seeger; Friedrich Grimminger; Ralph T Schermuly
Journal:  BMC Pulm Med       Date:  2008-12-17       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.